Thyrocare Technologies, one of India’s leading diagnostic and preventive healthcare service providers, reported strong growth in its Q2 FY26 financial results. The company showcased impressive year-on-year performance across key metrics, signaling robust business momentum.
For the quarter ended September 30, 2025, Thyrocare Technologies posted a net profit of ₹48 crore, marking a remarkable 79% increase compared to ₹27 crore in the same period last year. The growth reflects the company’s efficient cost management and expanding service network.
Revenue for the quarter rose 22% to ₹216.5 crore from ₹177.4 crore in Q2 FY25, driven by higher diagnostic tests and increased customer demand across pan-India locations.
EBITDA also saw a significant jump of 47.5%, reaching ₹71.3 crore against ₹48.3 crore in the previous year. This translates into an EBITDA margin of 32.9%, up from 27.2% YoY, highlighting improved operational efficiency and optimized resource utilization.
Disclaimer: This article is for informational purposes only. It is not intended to be investment advice or a recommendation to buy or sell any stock. Readers are advised to consult their financial advisor before making any investment decisions.
